

S 183

Short on Competition Act

Congress: 115 (2017–2019, Ended)

Chamber: Senate

Policy Area: Health

Introduced: Jan 20, 2017

Current Status: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Latest Action: Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Jan 20, 2017)

Official Text: <https://www.congress.gov/bill/115th-congress/senate-bill/183>

Sponsor

Name: Sen. Klobuchar, Amy [D-MN]

Party: Democratic • **State:** MN • **Chamber:** Senate

Cosponsors (3 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Lee, Mike [R-UT]	R · UT		Jan 20, 2017
Sen. Durbin, Richard J. [D-IL]	D · IL		Mar 5, 2018
Sen. Grassley, Chuck [R-IA]	R · IA		Mar 5, 2018

Committee Activity

Committee	Chamber	Activity	Date
Health, Education, Labor, and Pensions Committee	Senate	Referred To	Jan 20, 2017

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Short on Competition Act

This bill amends the Federal Food, Drug, and Cosmetic Act to require the Food and Drug Administration (FDA) to authorize importation of life-saving drugs for which there is, or is likely to be, a shortage. For a drug to be imported, the drug's manufacturer must intend to seek FDA approval of the drug as a generic drug. The FDA may deny importation of a drug for reasons related to safety or effectiveness.

Drugs in noncompetitive markets must be treated as being in a shortage for purposes of this bill and for purposes of expedited inspections and review. A drug is in a noncompetitive market if: (1) there are fewer than five holders of approved applications for commercially available brand name or generic versions of the drug, (2) the drug has been approved for at least 10 years, and (3) patents on the active ingredient of the drug have expired.

Actions Timeline

- **Jan 20, 2017:** Introduced in Senate
- **Jan 20, 2017:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions.